La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Boston Scientific Bilan de santé
Santé financière contrôle des critères 5/6
Boston Scientific possède un total de capitaux propres de $20.6B et une dette totale de $10.6B, ce qui porte son ratio d'endettement à 51.3%. Son actif total et son passif total sont $37.1B et de $16.5B. L'EBIT de Boston Scientific est $2.7B ce qui fait que son ratio de couverture des intérêts 10.7. Elle dispose de liquidités et de placements à court terme de $2.9B.
Informations clés
51.3%
Ratio d'endettement
US$10.57b
Dette
| Ratio de couverture des intérêts | 10.7x |
| Argent liquide | US$2.91b |
| Fonds propres | US$20.61b |
| Total du passif | US$16.50b |
| Total des actifs | US$37.11b |
Mises à jour récentes de la santé financière
Is Boston Scientific (NYSE:BSX) Using Too Much Debt?
May 10
Is Boston Scientific (NYSE:BSX) A Risky Investment?
Feb 02Does Boston Scientific (NYSE:BSX) Have A Healthy Balance Sheet?
Nov 03Boston Scientific (NYSE:BSX) Seems To Use Debt Quite Sensibly
Jul 25Here's Why Boston Scientific (NYSE:BSX) Can Manage Its Debt Responsibly
Apr 18Recent updates
The Strong Earnings Posted By Boston Scientific (NYSE:BSX) Are A Good Indication Of The Strength Of The Business
Aug 08Boston Scientific Q2 Earnings Preview: Can The Rally Continue?
Jul 17Here's Why We Think Boston Scientific (NYSE:BSX) Is Well Worth Watching
Jul 05Should You Investigate Boston Scientific Corporation (NYSE:BSX) At US$77.00?
Jun 21Boston Scientific Has Become A Standout Growth Story In Med-Tech
Jun 13Why We're Not Concerned About Boston Scientific Corporation's (NYSE:BSX) Share Price
Jun 08Is Boston Scientific (NYSE:BSX) Using Too Much Debt?
May 10Boston Scientific (NYSE:BSX) Is Reinvesting At Lower Rates Of Return
Apr 22Boston Scientific: Implications Of The Axonics-Medtronic Patent Clash
Apr 05A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Mar 26We Ran A Stock Scan For Earnings Growth And Boston Scientific (NYSE:BSX) Passed With Ease
Feb 29What You Can Learn From Boston Scientific Corporation's (NYSE:BSX) P/E
Feb 15Is Boston Scientific (NYSE:BSX) A Risky Investment?
Feb 02Boston Scientific (NYSE:BSX) Could Be Struggling To Allocate Capital
Jan 19Boston Scientific: Portfolio Updates Driving Top-Line Growth
Jan 17Boston Scientific: Continued M&A Drives More Growth
Jan 10Is Boston Scientific Corporation (NYSE:BSX) Worth US$56.1 Based On Its Intrinsic Value?
Dec 04Does Boston Scientific (NYSE:BSX) Have A Healthy Balance Sheet?
Nov 03Boston Scientific: Delivering Strong Growth, But Sector Derating Is A Big Issue
Oct 30ADVENT Offers Up An Early Present For Boston Scientific Investors
Aug 28Estimating The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Aug 24Boston Scientific (NYSE:BSX) Seems To Use Debt Quite Sensibly
Jul 25Boston Scientific Remains Operationally Sound But May Have Limited Upside
Jul 14Investors Could Be Concerned With Boston Scientific's (NYSE:BSX) Returns On Capital
Jul 10Boston Scientific Corporation (NYSE:BSX) Shares Could Be 29% Above Their Intrinsic Value Estimate
May 21Here's Why Boston Scientific (NYSE:BSX) Can Manage Its Debt Responsibly
Apr 18Returns On Capital At Boston Scientific (NYSE:BSX) Paint A Concerning Picture
Apr 03Boston Scientific Stands Out With Strong, Diversified Growth Profile
Feb 15Analyse de la situation financière
Passif à court terme: Les actifs à court terme de BSX ( $9.0B ) dépassent ses passifs à court terme ( $5.6B ).
Passif à long terme: Les actifs à court terme de BSX ( $9.0B ) ne couvrent pas ses passifs à long terme ( $10.9B ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: Le ratio dette nette/capitaux propres de BSX ( 37.1% ) est considéré comme satisfaisant.
Réduire la dette: Le ratio d'endettement de BSX a été réduit de 101.2% à 51.3% au cours des 5 dernières années.
Couverture de la dette: La dette de BSX est bien couverte par le flux de trésorerie opérationnel ( 24.9% ).
Couverture des intérêts: Les paiements d'intérêts de BSX sur sa dette sont bien couverts par l'EBIT ( 10.7 x couverture).